請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16043
標題: | 癌細胞中調控CCT-β表現程度對伴侶蛋白折疊與抗藥性之影響 Regulating CCT-β expression level affects chaperonin folding machinery and drug resistance in cancer cell |
作者: | Che-Kuan Chao 趙哲寬 |
指導教授: | 梁博煌 |
關鍵字: | 抗藥性癌症細胞,多重抗藥性蛋白,伴侶蛋白,細胞骨架,新藥開發, chaperonin,CCT-β,Multidrug resistance protein 1,tubulin, |
出版年 : | 2012 |
學位: | 碩士 |
摘要: | 近年來,對於癌症的運作機制已經越來越被研究透徹,治療方式也持續地有突破性的發展。然而,對於各式抗癌藥物,在長時間的治療下,癌症細胞所出現的抗藥性,仍然是癌症治療上難以突破的癥結點。Chaperonin containing t-complex polypeptide 1 (CCT) subunit β (CCT-β) 被發現在許多不同種類的癌症以及具抗藥性的癌症細胞中,都有過量表現的狀況(Lin et al., 2009)。因此在本論文中,我主要的目的即為觀察過量表現的CCT-β在癌症細胞中的特性,為此,我首先建立了CCT-β過量表現以及CCT-β抑制表現的兩種穩定細胞株,以觀察CCT-β在癌症細胞中所造成的影響。
首先檢視的,是CCT的蛋白質折疊能力。CCT的兩種受質actin與tubulin,是細胞骨架actin filament與microtubule不可或缺的組成物。在CCT-β過量表現的穩定細胞株中,actin與tubulin的兩種亞型均發現有顯著增加的情形,顯示過量表現的CCT-β能夠增加actin與tubulin的折疊及成熟。另一方面,CCT- Chaperonin containing t-complex polypeptide 1 (CCT) is a molecular chaperonin that facilitates the protein folding process in eukaryotic cytosol. The expression level of the CCT-β subunit was found elevated in a variety of drug-resistant tumor types (Lin et al., 2009). In this study, the main purpose is to examine the characteristics of up-regulating CCT-β in cancer cells. Initially, the classic substrates of CCT, actin and tubulin, were examined. Overexpression of CCT-β resulted in significantly elevated expression of both molecules, while knockdown of CCT-β gave no apparent difference. Therefore, up-regulation of CCT-β in cancer cells promotes more vigorous cytoskeleton formation. Next, other subunits of CCT were examined. In both CCT-β overexpress and knockdown stable clone, as well as paclitaxel-resistant cells, some but not all of the eight subunits were found to have synchronous changes with CCT-β in final protein amount. This phenomenon could be explained by the sub-assemblies during the complete CCT complex formation. Abnormally high level of CCT-β in cancer cells may hence break the balance of CCT subunits and affect the folding efficiency. On the other hand, expression level of CCT-β also correlated with the phosphorylation of Elk1, a transcription factor which is usually activated by MAPK family member p38. CCT-β up-regulation was found to induce the multi-drug resistance in cancer cells and stable clone, and the expression of multidrug-resistant protein (MDR1) was induced by CCT-β up-regulation. RNA interference experiments revealed that Elk1 knockdown effectively repressed MDR1 expression and drug resistance in CCT-β up-regulated cells. Interestingly, CCT-β seemed able to affect the phosphorylation level of Elk1, indicating that MDR1 expression and drug resistance in cancer cells may be controlled by MAPK signaling and stress-induced CCT-β. Moreover, a recently screened compound called R379603 showed significant apoptosis effects on CCT-β up-regulated cancer cells. R379603 led to CCT-β up-regulated cell death by introducing ER stress in cells, causing caspase activation and apoptosis. Since this is the route bypassing MDR1-related drug resistance, R379603 may therefore be a promising candidate for treating patients with elevated CCT-βand MDR1 expression. Overall, these studies uncovered two possible roles of CCT-β in CCT-β up-regulated cancer cells: enhancing folding efficiencies of cytoskeleton molecules, and inducing multi-drug resistance. Since CCT-β may be leading CCT assembly and substrate folding, the importance of CCT-β should be further investigated. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16043 |
全文授權: | 未授權 |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.67 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。